Symbols / CELU Stock $1.12 -4.27% Celularity Inc.
CELU (Stock) Chart
About
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Stock Fundamentals
Scroll to Statements| Market Cap | 32.30M | Enterprise Value | 99.79M | Income | -80.65M | Sales | 40.58M | Book/sh | -0.71 | Cash/sh | 0.00 |
| Dividend Yield | — | Payout | 0.00% | Employees | 123 | IPO | — | P/E | — | Forward P/E | -1.96 |
| PEG | — | P/S | 0.80 | P/B | -1.57 | P/C | — | EV/EBITDA | -2.41 | EV/Sales | 2.46 |
| Quick Ratio | 0.10 | Current Ratio | 0.16 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -3.33 | EPS next Y | -0.57 |
| EPS Growth | — | Revenue Growth | -43.20% | Earnings | 2025-08-18 | ROA | -25.03% | ROE | — | ROIC | — |
| Gross Margin | 50.61% | Oper. Margin | -243.17% | Profit Margin | -198.75% | Shs Outstand | 28.84M | Shs Float | 18.42M | Short Float | 4.50% |
| Short Ratio | 0.78 | Short Interest | — | 52W High | 4.35 | 52W Low | 1.01 | Beta | 0.70 | Avg Volume | 155.26K |
| Volume | 74.59K | Target Price | — | Recom | None | Prev Close | $1.17 | Price | $1.12 | Change | -4.27% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-09 | up | WBB Securities | Hold → Buy | $6 |
| 2025-08-18 | init | WBB Securities | — → Speculative Buy | $6 |
- Celularity sells biomaterials assets, cuts nearly $13M of debt - Stock Titan ue, 21 Apr 2026 12
- CELU Celularity tops Q3 2025 EPS estimates and posts sharp revenue growth, as shares dip 2.08%. - Guidance Upgrade - Cổng thông tin điện tử Tỉnh Sơn La hu, 23 Apr 2026 10
- CELU Celularity tops Q3 2025 EPS estimates and posts sharp revenue growth, as shares dip 2.08%. - Special Dividend - Cổng thông tin điện tử tỉnh Tây Ninh hu, 23 Apr 2026 00
- Celularity Inc. Notifies Nasdaq of Non-Compliance with Listing Rules Due to Delay in Annual Report Filing - Quiver Quantitative Fri, 17 Apr 2026 20
- 12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga ue, 21 Apr 2026 21
- Family trust reports 20.1% Celularity (CELU) stake from $10M financing - Stock Titan Wed, 22 Apr 2026 14
- Celularity Closes NexGel Asset Sale, Refocuses on Cell Therapy - TipRanks ue, 21 Apr 2026 13
- Is Celularity (CELU) Stock a Market Leader | Price at $1.35, Down 0.74% - Fast Rising Stocks - UBND thành phố Hải Phòng Fri, 10 Apr 2026 07
- Celularity (CELU) What Lies Ahead | Celularity Inc posts 42.5% EPS beat, narrower loss - Distressed Pick - Cổng thông tin điện tử Tỉnh Sơn La Wed, 22 Apr 2026 22
- Celularity (NASDAQ: CELU) closes NexGel asset sale as Helena note default looms - Stock Titan ue, 21 Apr 2026 13
- Celularity (NASDAQ: CELU) EVP RSUs vest into shares with tax withholding - Stock Titan Wed, 15 Apr 2026 20
- RSU vesting lifts Celularity (CELU) insider holdings after tax withholding - Stock Titan Wed, 15 Apr 2026 20
- Celularity (NASDAQ: CELU) CEO gains shares from RSU vesting - Stock Titan Wed, 15 Apr 2026 20
- Celularity’s $35M license shifts focus to placental longevity therapies - Stock Titan ue, 10 Mar 2026 07
- Barach Family Trust backs Celularity (CELU) with $10M notes and 9.56% stake - Stock Titan Fri, 03 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
54.22
+138.11%
|
22.77
+26.68%
|
17.98
-15.75%
|
21.34
|
| Operating Revenue |
|
54.22
+138.11%
|
22.77
+26.68%
|
17.98
-15.75%
|
21.34
|
| Cost Of Revenue |
|
14.99
-6.41%
|
16.02
-18.56%
|
19.66
+103.72%
|
9.65
|
| Reconciled Cost Of Revenue |
|
8.82
-0.73%
|
8.88
-28.47%
|
12.42
+310.24%
|
3.03
|
| Gross Profit |
|
39.23
+480.77%
|
6.75
+499.70%
|
-1.69
-114.47%
|
11.68
|
| Operating Expense |
|
77.78
-6.55%
|
83.23
-43.21%
|
146.58
-9.46%
|
161.89
|
| Research And Development |
|
17.39
-42.93%
|
30.46
-61.12%
|
78.36
-11.31%
|
88.35
|
| Selling General And Administration |
|
58.64
+15.95%
|
50.58
-23.39%
|
66.02
-7.46%
|
71.34
|
| Total Expenses |
|
92.77
-6.53%
|
99.25
-40.30%
|
166.24
-3.09%
|
171.54
|
| Operating Income |
|
-38.55
+49.59%
|
-76.48
+48.42%
|
-148.27
+1.29%
|
-150.20
|
| Total Operating Income As Reported |
|
-38.36
+80.05%
|
-192.29
-651.12%
|
-25.60
+76.53%
|
-109.06
|
| EBITDA |
|
-43.71
+76.24%
|
-183.95
-878.08%
|
23.64
+126.83%
|
-88.11
|
| Normalized EBITDA |
|
-40.39
+45.64%
|
-74.30
+47.35%
|
-141.13
+1.12%
|
-142.74
|
| Reconciled Depreciation |
|
7.92
-15.04%
|
9.32
-1.19%
|
9.44
+7.02%
|
8.82
|
| EBIT |
|
-51.63
+73.29%
|
-193.27
-1460.58%
|
14.21
+114.66%
|
-96.93
|
| Total Unusual Items |
|
-3.32
+96.97%
|
-109.64
-166.54%
|
164.78
+201.64%
|
54.63
|
| Total Unusual Items Excluding Goodwill |
|
-3.32
+96.97%
|
-109.64
-166.54%
|
164.78
+201.64%
|
54.63
|
| Special Income Charges |
|
-3.71
+96.79%
|
-115.81
-194.41%
|
122.67
+198.13%
|
41.15
|
| Other Special Charges |
|
3.91
|
—
|
—
|
—
|
| Impairment Of Capital Assets |
|
0.00
-100.00%
|
112.35
+3012.11%
|
3.61
|
0.00
|
| Restructuring And Mergern Acquisition |
|
-0.19
+99.82%
|
-104.34
+17.37%
|
-126.28
-206.91%
|
-41.15
|
| Write Off |
|
0.00
-100.00%
|
107.80
|
0.00
|
—
|
| Net Income |
|
-57.89
+70.51%
|
-196.29
-1483.14%
|
14.19
+114.18%
|
-100.12
|
| Pretax Income |
|
-57.89
+70.51%
|
-196.28
-1481.80%
|
14.21
+114.19%
|
-100.10
|
| Net Non Operating Interest Income Expense |
|
-5.93
-120.15%
|
-2.69
-838.36%
|
0.36
+112.86%
|
-2.84
|
| Interest Expense Non Operating |
|
6.26
+107.76%
|
3.02
|
0.00
-100.00%
|
3.17
|
| Net Interest Income |
|
-5.93
-120.15%
|
-2.69
-838.36%
|
0.36
+112.86%
|
-2.84
|
| Interest Expense |
|
6.26
+107.76%
|
3.02
|
0.00
-100.00%
|
3.17
|
| Interest Income Non Operating |
|
0.33
+3.44%
|
0.32
-12.33%
|
0.36
+9.94%
|
0.33
|
| Interest Income |
|
0.33
+3.44%
|
0.32
-12.33%
|
0.36
+9.94%
|
0.33
|
| Other Income Expense |
|
-13.41
+88.55%
|
-117.11
-172.24%
|
162.11
+206.18%
|
52.95
|
| Other Non Operating Income Expenses |
|
-10.09
-35.14%
|
-7.47
-179.77%
|
-2.67
-58.68%
|
-1.68
|
| Gain On Sale Of Security |
|
0.40
-93.54%
|
6.16
-85.36%
|
42.11
+212.33%
|
13.48
|
| Gain On Sale Of Business |
|
—
|
—
|
—
|
0.00
|
| Tax Provision |
|
0.00
-100.00%
|
0.01
-23.08%
|
0.01
-35.00%
|
0.02
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-57.89
+70.51%
|
-196.29
-1483.14%
|
14.19
+114.18%
|
-100.12
|
| Net Income From Continuing Operation Net Minority Interest |
|
-57.89
+70.51%
|
-196.29
-1483.14%
|
14.19
+114.18%
|
-100.12
|
| Net Income From Continuing And Discontinued Operation |
|
-57.89
+70.51%
|
-196.29
-1483.14%
|
14.19
+114.18%
|
-100.12
|
| Net Income Continuous Operations |
|
-57.89
+70.51%
|
-196.29
-1483.14%
|
14.19
+114.18%
|
-100.12
|
| Normalized Income |
|
-54.58
+37.02%
|
-86.65
+42.46%
|
-150.58
+2.69%
|
-154.75
|
| Net Income Common Stockholders |
|
-57.89
+70.51%
|
-196.29
-1483.14%
|
14.19
+114.18%
|
-100.12
|
| Diluted EPS |
|
-2.64
+76.04%
|
-11.02
-1260.00%
|
0.95
+106.38%
|
-14.90
|
| Basic EPS |
|
-2.64
+76.04%
|
-11.02
-1191.09%
|
1.01
+106.78%
|
-14.90
|
| Basic Average Shares |
|
21.89
+22.89%
|
17.81
+27.32%
|
13.99
+108.64%
|
6.71
|
| Diluted Average Shares |
|
21.89
+22.89%
|
17.81
+18.89%
|
14.98
+123.44%
|
6.71
|
| Diluted NI Availto Com Stockholders |
|
-57.89
+70.51%
|
-196.29
-1483.14%
|
14.19
+114.18%
|
-100.12
|
| Amortization |
|
1.75
-20.06%
|
2.19
+0.00%
|
2.19
+0.05%
|
2.19
|
| Amortization Of Intangibles Income Statement |
|
1.75
-20.06%
|
2.19
+0.00%
|
2.19
+0.05%
|
2.19
|
| Depreciation Amortization Depletion Income Statement |
|
1.75
-20.06%
|
2.19
+0.00%
|
2.19
+0.05%
|
2.19
|
| Depreciation And Amortization In Income Statement |
|
1.75
-20.06%
|
2.19
+0.00%
|
2.19
+0.05%
|
2.19
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
143.89
|
| Current Assets |
|
19.79
|
| Cash Cash Equivalents And Short Term Investments |
|
0.23
|
| Cash And Cash Equivalents |
|
0.23
|
| Receivables |
|
12.12
|
| Accounts Receivable |
|
10.05
|
| Gross Accounts Receivable |
|
15.88
|
| Allowance For Doubtful Accounts Receivable |
|
-5.84
|
| Inventory |
|
5.75
|
| Prepaid Assets |
|
1.37
|
| Other Current Assets |
|
0.33
|
| Total Non Current Assets |
|
124.10
|
| Net PPE |
|
78.82
|
| Gross PPE |
|
106.10
|
| Accumulated Depreciation |
|
-27.28
|
| Properties |
|
0.00
|
| Buildings And Improvements |
|
—
|
| Machinery Furniture Equipment |
|
7.78
|
| Construction In Progress |
|
0.02
|
| Other Properties |
|
25.08
|
| Leases |
|
73.21
|
| Goodwill And Other Intangible Assets |
|
18.35
|
| Goodwill |
|
7.35
|
| Other Intangible Assets |
|
11.00
|
| Other Non Current Assets |
|
26.93
|
| Total Liabilities Net Minority Interest |
|
102.93
|
| Current Liabilities |
|
67.30
|
| Payables And Accrued Expenses |
|
22.78
|
| Payables |
|
14.14
|
| Accounts Payable |
|
14.14
|
| Current Accrued Expenses |
|
8.63
|
| Current Debt And Capital Lease Obligation |
|
39.24
|
| Current Debt |
|
39.24
|
| Other Current Borrowings |
|
39.24
|
| Current Capital Lease Obligation |
|
—
|
| Current Deferred Liabilities |
|
2.83
|
| Current Deferred Revenue |
|
2.83
|
| Other Current Liabilities |
|
2.45
|
| Total Non Current Liabilities Net Minority Interest |
|
35.63
|
| Long Term Debt And Capital Lease Obligation |
|
26.18
|
| Long Term Debt |
|
—
|
| Long Term Capital Lease Obligation |
|
26.18
|
| Non Current Deferred Liabilities |
|
3.19
|
| Non Current Deferred Revenue |
|
3.19
|
| Non Current Deferred Taxes Liabilities |
|
0.01
|
| Other Non Current Liabilities |
|
1.90
|
| Preferred Securities Outside Stock Equity |
|
—
|
| Stockholders Equity |
|
40.96
|
| Common Stock Equity |
|
40.96
|
| Capital Stock |
|
0.02
|
| Common Stock |
|
0.02
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
19.38
|
| Ordinary Shares Number |
|
19.38
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
882.73
|
| Retained Earnings |
|
-841.79
|
| Gains Losses Not Affecting Retained Earnings |
|
0.00
|
| Treasury Stock |
|
—
|
| Other Equity Adjustments |
|
—
|
| Total Equity Gross Minority Interest |
|
40.96
|
| Total Capitalization |
|
40.96
|
| Working Capital |
|
-47.51
|
| Invested Capital |
|
80.20
|
| Total Debt |
|
65.42
|
| Net Debt |
|
39.01
|
| Capital Lease Obligations |
|
26.18
|
| Net Tangible Assets |
|
22.61
|
| Tangible Book Value |
|
22.61
|
| Derivative Product Liabilities |
|
4.36
|
| Interest Payable |
|
0.00
|
| Notes Receivable |
|
2.07
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-6.40
+83.45%
|
-38.69
+71.94%
|
-137.88
-25.23%
|
-110.10
|
| Cash Flow From Continuing Operating Activities |
|
-6.40
+83.45%
|
-38.69
+71.94%
|
-137.88
-25.23%
|
-110.10
|
| Net Income From Continuing Operations |
|
-57.89
+70.51%
|
-196.29
-1483.14%
|
14.19
+114.18%
|
-100.12
|
| Depreciation Amortization Depletion |
|
7.92
-15.04%
|
9.32
-1.19%
|
9.44
+7.02%
|
8.82
|
| Depreciation |
|
6.17
-13.49%
|
7.13
|
—
|
—
|
| Amortization Cash Flow |
|
1.75
-20.06%
|
2.19
|
—
|
—
|
| Depreciation And Amortization |
|
7.92
-15.04%
|
9.32
-1.19%
|
9.44
+7.02%
|
8.82
|
| Amortization Of Intangibles |
|
1.75
-20.06%
|
2.19
|
—
|
—
|
| Other Non Cash Items |
|
5.39
+105.84%
|
-92.31
+25.35%
|
-123.67
-272.65%
|
-33.19
|
| Stock Based Compensation |
|
11.73
-21.91%
|
15.02
-5.29%
|
15.86
-60.37%
|
40.01
|
| Provisionand Write Offof Assets |
|
0.27
-89.42%
|
2.56
+36.44%
|
1.88
+529.87%
|
0.30
|
| Asset Impairment Charge |
|
0.47
-99.79%
|
225.53
+4896.26%
|
4.51
|
0.00
|
| Deferred Tax |
|
—
|
0.00
+100.00%
|
-0.00
+99.93%
|
-1.35
|
| Deferred Income Tax |
|
—
|
0.00
+100.00%
|
-0.00
+99.93%
|
-1.35
|
| Operating Gains Losses |
|
3.51
+160.93%
|
-5.76
+86.32%
|
-42.11
-212.33%
|
-13.48
|
| Gain Loss On Investment Securities |
|
-0.40
+93.09%
|
-5.76
+86.32%
|
-42.11
-212.33%
|
-13.48
|
| Change In Working Capital |
|
22.20
+582.66%
|
3.25
+118.09%
|
-17.98
-62.19%
|
-11.08
|
| Change In Receivables |
|
-3.97
+41.88%
|
-6.83
-90.49%
|
-3.58
-87.74%
|
-1.91
|
| Changes In Account Receivables |
|
-3.97
+41.88%
|
-6.83
-90.49%
|
-3.58
-87.74%
|
-1.91
|
| Change In Inventory |
|
6.28
+826.47%
|
-0.86
+94.88%
|
-16.89
-163.02%
|
-6.42
|
| Change In Prepaid Assets |
|
0.91
-83.86%
|
5.61
+11340.82%
|
0.05
-98.40%
|
3.07
|
| Change In Payables And Accrued Expense |
|
18.37
+419.75%
|
3.54
+100.62%
|
1.76
+46.10%
|
1.21
|
| Change In Accrued Expense |
|
9.13
+284.08%
|
-4.96
-205.35%
|
4.71
+361.52%
|
-1.80
|
| Change In Payable |
|
9.24
+8.73%
|
8.50
+388.23%
|
-2.95
-198.04%
|
3.01
|
| Change In Account Payable |
|
9.24
+8.73%
|
8.50
+388.23%
|
-2.95
-198.04%
|
3.01
|
| Change In Other Working Capital |
|
0.61
-66.39%
|
1.80
+162.06%
|
0.69
+109.79%
|
-7.03
|
| Investing Cash Flow |
|
0.51
+112.70%
|
-4.05
+22.69%
|
-5.24
+11.30%
|
-5.90
|
| Cash Flow From Continuing Investing Activities |
|
0.51
+112.70%
|
-4.05
+22.69%
|
-5.24
+11.30%
|
-5.90
|
| Capital Expenditure |
|
-0.16
+96.02%
|
-4.05
+22.69%
|
-5.24
+15.59%
|
-6.20
|
| Capital Expenditure Reported |
|
-0.16
+84.64%
|
-1.05
+79.98%
|
-5.24
+15.59%
|
-6.20
|
| Net Business Purchase And Sale |
|
-1.50
|
0.00
|
—
|
0.00
|
| Purchase Of Business |
|
-1.50
|
0.00
|
—
|
—
|
| Gain Loss On Sale Of Business |
|
—
|
—
|
—
|
0.00
|
| Net Intangibles Purchase And Sale |
|
0.00
+100.00%
|
-3.00
|
0.00
|
—
|
| Purchase Of Intangibles |
|
0.00
+100.00%
|
-3.00
|
0.00
|
—
|
| Net Other Investing Changes |
|
2.17
|
—
|
—
|
0.30
|
| Financing Cash Flow |
|
6.70
-72.19%
|
24.09
-79.89%
|
119.84
+21.59%
|
98.56
|
| Cash Flow From Continuing Financing Activities |
|
6.70
-72.19%
|
24.09
-79.89%
|
119.84
+21.59%
|
98.56
|
| Net Issuance Payments Of Debt |
|
-13.90
+6.16%
|
-14.81
-117.28%
|
85.69
|
0.00
|
| Issuance Of Debt |
|
3.62
+81.10%
|
2.00
-97.67%
|
85.69
+1613.82%
|
5.00
|
| Repayment Of Debt |
|
-17.52
-4.22%
|
-16.81
|
0.00
+100.00%
|
-5.00
|
| Long Term Debt Issuance |
|
—
|
17.37
-62.64%
|
46.49
|
—
|
| Net Long Term Debt Issuance |
|
—
|
17.37
-62.64%
|
46.49
|
—
|
| Short Term Debt Issuance |
|
3.62
+81.10%
|
2.00
-94.90%
|
39.20
+684.00%
|
5.00
|
| Short Term Debt Payments |
|
-17.52
-4.22%
|
-16.81
|
0.00
+100.00%
|
-5.00
|
| Net Short Term Debt Issuance |
|
-13.90
+6.16%
|
-14.81
-137.78%
|
39.20
|
0.00
|
| Net Common Stock Issuance |
|
6.00
-72.59%
|
21.89
-40.07%
|
36.52
-56.21%
|
83.40
|
| Common Stock Payments |
|
—
|
—
|
—
|
0.00
|
| Repurchase Of Capital Stock |
|
—
|
—
|
—
|
0.00
|
| Proceeds From Stock Option Exercised |
|
15.06
-19.36%
|
18.67
+2066.24%
|
0.86
-85.69%
|
6.02
|
| Net Other Financing Charges |
|
-0.46
+72.25%
|
-1.65
+48.86%
|
-3.23
-135.39%
|
9.14
|
| Changes In Cash |
|
0.81
+104.37%
|
-18.64
+19.91%
|
-23.27
-33.47%
|
-17.44
|
| Beginning Cash Position |
|
10.16
-64.71%
|
28.80
-44.69%
|
52.08
-25.08%
|
69.51
|
| End Cash Position |
|
10.98
+8.01%
|
10.16
-64.71%
|
28.80
-44.69%
|
52.08
|
| Free Cash Flow |
|
-6.56
+84.64%
|
-42.73
+70.14%
|
-143.11
-23.06%
|
-116.30
|
| Interest Paid Supplemental Data |
|
0.14
-86.58%
|
1.07
|
0.00
-100.00%
|
0.15
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
0.00
|
0.00
|
| Common Stock Issuance |
|
6.00
-72.59%
|
21.89
-40.07%
|
36.52
-56.21%
|
83.40
|
| Issuance Of Capital Stock |
|
6.00
-72.59%
|
21.89
-40.07%
|
36.52
-56.21%
|
83.40
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Sale Of Business |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-21 View
- 42026-04-15 View
- 42026-04-15 View
- 42026-04-15 View
- 8-K2026-03-10 View
- 8-K2026-03-05 View
- 8-K2026-01-21 View
- 42026-01-14 View
- 42026-01-14 View
- 42026-01-14 View
- 42026-01-14 View
- 42025-12-30 View
- 42025-12-30 View
- 42025-12-30 View
- 42025-12-30 View
- 8-K2025-12-23 View
- 42025-12-22 View
- 42025-12-22 View
- 42025-12-22 View
- 8-K2025-12-19 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|